Key Development
Bristol Myers Squibb has delivered two positive Phase 3 readouts on the same day, but the programs represent very different growth strategies. Admilparant targets idiopathic pulmonary fibrosis through LPA1 inhibition, while RYZ101 is an Actinium-225 radiopharmaceutical for SSTR-positive gastroenteropancreatic neuroendocrine tumors that have progressed after Lu177-based therapy.
In ALOFT-IPF, admilparant 60 mg twice daily met the primary endpoint by producing a statistically significant benefit versus placebo in absolute change in forced vital capacity at Week 52. The 120 mg dose did not achieve statistical significance, although BMS said it also slowed FVC decline. Full effect sizes have not yet been disclosed.
Separately, ACTION-1 met its primary endpoint at a planned interim analysis. BMS reported a statistically significant and clinically meaningful improvement in progression-free survival with RYZ101, or 225Ac-DOTATATE, versus investigator’s choice of standard therapy in patients whose GEP-NETs had progressed following Lu177 treatment. Hazard ratios and median PFS have not yet been released.
Why It Matters
- BMS needs new growth drivers. Eliquis and Opdivo accounted for more than half of second-quarter sales, while both could face U.S. loss of exclusivity in 2028.
- Admilparant could introduce a new IPF mechanism. Jascayd became the first new U.S. IPF treatment in more than a decade when the FDA approved it in 2025.
- RYZ101 potentially validates Actinium-225 at pivotal scale. BMS describes ACTION-1 as the first positive Phase 3 study of an alpha-isotope targeted radiopharmaceutical in any indication.
- Neither program is fully de-risked. Admilparant raises dose-response questions; RYZ101 still lacks disclosed magnitude of benefit.
Healthcare Insight Analysis
Healthcare Insight believes these readouts are best understood as a portfolio construction story.
Admilparant addresses one of the most difficult categories in respiratory medicine.
The positive 60 mg result matters.
But the failure of the 120 mg arm to reach statistical significance introduces an important question: why did the higher dose not produce a clearer benefit?
A conventional dose-response relationship would normally increase confidence in mechanism and reproducibility.
BMS will therefore need the full dataset to answer:
How large was the FVC benefit?
How consistent was it across subgroups?
What explains the dose pattern?
What was the detailed liver-safety profile?
Those questions matter because concerns had emerged before the readout over liver toxicity, including a fatal case involving acute hepatic injury. Fierce reported that BMS management later said the acute liver injury occurred in the 120 mg arm and was adjudicated as unlikely to be treatment-related.
Commercial positioning will also be more demanding than it might have been several years ago.
The U.S. IPF market now includes Jascayd, approved in 2025, while generic nintedanib entered in 2026.
Admilparant therefore needs to demonstrate not simply statistical efficacy, but a compelling efficacy–tolerability–combination profile.
RYZ101 represents a different strategic logic.
Its differentiation is partly physics rather than receptor biology.
Existing Lu177-based radiopharmaceuticals deliver beta radiation. RYZ101 uses Actinium-225, an alpha emitter capable of delivering highly energetic, short-range radiation and producing double-strand DNA damage in targeted tumor cells.
The key strategic decision in ACTION-1 was to study patients after progression on Lu177.
That allows BMS to establish a clinically clear sequencing position rather than immediately challenge Lu177 in the frontline setting.
If full results show a meaningful PFS advantage, RYZ101 could occupy a defined post-Lu177 niche with relatively little ambiguity around unmet need.
The commercial opportunity, however, extends beyond the molecule.
Radiopharmaceuticals require specialized isotope sourcing, manufacturing and delivery. BMS has built RayzeBio infrastructure capable of manufacturing clinical doses and delivering them to treatment centers within days; at full capacity, the site is designed to supply tens of thousands of doses annually.
That means the potential moat is not just:
drug target.
It is:
target + isotope + manufacturing + logistics.
This is particularly important for Actinium-225, where supply-chain scalability remains a critical industry constraint.
Market Implications
BMS: the two wins reduce pipeline risk but do not yet solve the 2028 patent-cliff challenge.
IPF competitors: LPA1 could become a new mechanism if the full efficacy and safety profile supports combination use.
Radiopharma companies: ACTION-1 could materially strengthen confidence in Actinium-225 as a scalable therapeutic isotope.
Investors: the next decisive information is quantitative — FVC delta for admilparant and PFS hazard ratio for RYZ101.
ANALYTICAL MATRIX
| Asset | Current Signal | Strategic Opportunity | Remaining Risk |
| Admilparant | 60 mg Phase 3 win | First-in-class LPA1 | 120 mg miss, effect size unknown |
| RYZ101 | Positive PFS interim | First pivotal alpha-RPT success | Full PFS data pending |
| IPF | Persistent unmet need | Add-on / alternative therapy | More competitive market |
| GEP-NET | Post-Lu177 treatment gap | Clear sequencing niche | Rare-disease scale |
| BMS portfolio | Two pivotal wins | Post-2028 growth | Commercial execution |
The next questions are straightforward but consequential:
Does admilparant deliver enough FVC preservation at 60 mg to become clinically differentiated?
And:
Does RYZ101 deliver a large enough PFS advantage to convert Actinium-225 from an experimental radiopharmaceutical platform into a scalable oncology business?
If both answers are yes, October 12, 2026 may ultimately matter for more than two Phase 3 headlines.
It could mark the point at which BMS began showing that its post-Eliquis and post-Opdivo portfolio had credible growth engines of its own.